Is Retatrutide FDA-Approved?

Retatrutide (also known by its research designation LY3437943) has not been approved by the U.S. Food and Drug Administration for any indication. It is classified as an investigational drug, meaning it is still undergoing clinical testing to determine its safety and efficacy before it can be considered for approval.

The medication is being developed by Eli Lilly, the same company behind tirzepatide (Mounjaro and Zepbound). While Phase 2 clinical trial results were highly promising -- showing up to 24.2% body weight loss at the highest dose -- the drug must complete Phase 3 trials and receive a formal FDA review before it can be prescribed to patients.

As of 2025, retatrutide is in Phase 3 clinical trials. Here is what each phase means in the drug development process:

Phase 1: Small studies testing safety and dosing in healthy volunteers or a small number of patients. Retatrutide completed this phase.

Phase 2: Medium-sized studies testing efficacy and side effects. Retatrutide completed this phase with results published in The New England Journal of Medicine showing record-breaking weight loss.

Phase 3: Large-scale studies confirming efficacy and safety across diverse populations. This is where retatrutide currently sits. These trials typically involve thousands of participants and run for one to two years or longer.

After Phase 3: If results are positive, Eli Lilly will submit a New Drug Application to the FDA, which then conducts its own review. This entire process from Phase 3 completion to approval typically takes two to three years.

The FDA approval process exists to protect patients. It ensures that a medication's benefits outweigh its risks, that the manufacturing process produces a consistent and pure product, and that the labeling accurately reflects the drug's effects. Without FDA approval, there is no guarantee that a product marketed as retatrutide contains the correct compound at the correct dose, is free of contaminants, or has been stored properly.

This is especially important because the enthusiasm surrounding retatrutide's weight loss results has created a market for counterfeit or unregulated products. Some online vendors and overseas pharmacies claim to sell retatrutide for research purposes or personal use. These products have not been tested for purity, potency, or safety and may pose serious health risks.

Two GLP-1-based medications are currently FDA-approved and widely available for weight management:

Semaglutide: Approved as Wegovy for chronic weight management and as Ozempic for type 2 diabetes. Also available as compounded semaglutide from licensed 503A and 503B pharmacies.

Tirzepatide: Approved as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes. Also available as compounded tirzepatide from licensed pharmacies.

These are proven, FDA-reviewed treatments with well-established safety profiles supported by large-scale clinical trials. For patients seeking effective GLP-1 therapy, these medications are the current standard of care while retatrutide continues through the approval process.

Both compounded semaglutide and tirzepatide are dispensed in multi-dose vials and dosed with U-100 insulin syringes using the formula: units = (dose in mg / concentration in mg/mL) x 100. A dosage calculator removes the guesswork from this conversion and ensures you draw the correct amount every time.